As estrogen is pro-proliferative and fuels tumor growth in the breast, the inflammation–aromatase–estrogen axis is postulated to drive tumor progression, especially in postmenopausal women where the in situ synthesized estrogen in the breast outweighs ovary-produced estrogen [102]. Here, CYP19A1 is linked to neoplasm.